Medicare Ends Automatic Extra Payments for FDA 'Breakthrough' Medical Devices

Key facts

The regulatory link between accelerated FDA market authorization and automatic Medicare financial support has been officially severed, according to reporting by Katie Palmer. For years, medical technology developers relied on FDA breakthrough designation not only as a mechanism to accelerate premarket safety review, but as a critical gateway to securing favorable reimbursement from Medicare.

Under previous policy arrangements, when the FDA granted breakthrough status to a novel technology—ranging from AI-driven diagnostic software to complex cardiovascular devices—the decision carried major commercial weight. Upon receiving market clearance, these technologies routinely gained access to automatic or expedited add-on payments from the Centers for Medicare & Medicaid Services (CMS). These extra payments, distributed through mechanisms such as the New Technology Add-On Payment (NTAP) program for inpatient hospital stays or pass-through status in outpatient settings, provided supplemental funds on top of standard bundled reimbursement rates. The extra money was intended to cushion the financial impact on hospitals buying expensive new systems.

With the termination of automatic eligibility, breakthrough devices are stripped of their special status within the Medicare reimbursement pipeline. CMS will no longer assume that an expedited safety approval by the FDA warrants additional taxpayer-funded payments to healthcare providers. Instead, manufacturers must navigate standard reimbursement administrative channels. To receive payments beyond the baseline Diagnosis-Related Group (DRG) or Ambulatory Payment Classification (APC) bundled rates, developers must independently prove that their devices deliver superior clinical outcomes specifically for elderly and disabled patients covered by Medicare. Device makers can no longer rely on FDA regulatory milestones alone to guarantee higher hospital adoption or commercial viability.

Why it matters

The elimination of automatic supplemental Medicare payments alters the financial calculus for the entire medical device ecosystem, affecting venture capital allocation, hospital purchasing decisions, and patient care delivery.

For medical device manufacturers and venture capital funds, the policy change introduces substantial commercial uncertainty. In medical technology financing, FDA breakthrough designation long functioned as a primary de-risking milestone. Investors frequently backed early-stage medtech startups under the assumption that breakthrough status would lock in elevated Medicare reimbursement, ensuring rapid market penetration upon regulatory clearance. Without automatic extra payments, venture funding may shift away from high-capital hardware innovations toward less regulated digital tools or mature technology iterations that carry lower regulatory and reimbursement risk.

For hospitals and clinical providers, particularly safety-net institutions operating on thin financial margins, the decision creates immediate operational challenges. When a hospital adopts an expensive, novel device without supplemental Medicare coverage, it must absorb the cost difference between the purchase price and fixed bundled reimbursement rates. As a consequence, many hospitals may choose to delay purchasing innovative breakthrough tools until comprehensive coverage policies are explicitly established by regional Medicare contractors.

For Medicare beneficiaries, the impact represents a tension between financial stewardship and timely care access. While the policy aims to protect the Medicare Trust Fund from overpaying for unproven or marginally effective novel technologies, it may simultaneously create multi-year delays before Medicare recipients gain widespread access to state-of-the-art treatments that have already been cleared by federal safety regulators.

The intersection of medical device regulation and federal reimbursement has long been a source of administrative friction in Washington. The FDA Breakthrough Devices Program was created under Title III of the 21st Century Cures Act, signed into law in December 2016. The statutory program aimed to expedite the development and regulatory review of medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating human conditions. To qualify, a device must offer a significant technological breakthrough, present clear advantages over existing approved options, or offer a treatment where no alternative exists.

However, FDA clearance and Medicare reimbursement are governed by fundamentally different statutory mandates. While the FDA determines whether a device is safe and effective for its intended target population, CMS operates under the Social Security Act, which requires Medicare items and services to be "reasonable and necessary" for the specific health needs of the Medicare population—a demographic predominantly aged 65 and older with higher rates of multi-morbidity.

This structural division led to what industry executives called the reimbursement "valley of death," where devices cleared by the FDA languished for years without dedicated Medicare payment codes or coverage policies. To solve this, federal officials in late 2020 finalized the Medicare Coverage of Innovative Technology (MCIT) rule, which sought to guarantee four years of immediate national Medicare coverage to any device granted FDA breakthrough clearance.

However, CMS repealed the MCIT rule in late 2021 following widespread public health concerns that clinical trials submitted for FDA approval rarely included sufficient data on elderly patients or those with multiple chronic illnesses. In 2023, CMS proposed a replacement framework known as the Transformed Coverage for Efficient Technologies (TCET) pathway, emphasizing conditional coverage alongside rigorous post-market evidence development. The complete end of automatic add-on payments represents the final phase of unwinding automatic coverage mechanisms in favor of strict, evidence-based evaluation.

Reaction

The conclusion of automatic Medicare add-on payments for breakthrough devices reflects a long-standing debate among industry trade groups, patient advocacy organizations, and federal health policymakers.

Trade organizations representing the medical device industry, including the Advanced Medical Technology Association (AdvaMed), have consistently expressed concern over policies that complicate or delay Medicare reimbursement. Industry representatives argue that removing predictable payment pathways discourages venture capital investment in high-risk, high-reward medical technologies. They contend that requiring device makers to perform separate, lengthy clinical trials specifically tailored to Medicare payment criteria increases development costs, pushes small biotechnology firms toward bankruptcy, and ultimately slows US innovation relative to international markets.

Conversely, health economists, Medicare payment advisory experts, and taxpayer advocacy groups have commended CMS for upholding strict statutory coverage criteria. Critics of automatic reimbursement argue that providing higher payments solely based on an FDA administrative designation created fiscal risk for the Medicare Trust Fund without guaranteeing that patients received measurably better clinical outcomes. Policymakers supporting the shift maintain that public reimbursement should strictly reward demonstrated clinical effectiveness rather than regulatory novelty, ensuring that Medicare funds are spent prudently on proven treatments.

What we don't know yet

Significant questions remain regarding how CMS will manage the operational transition for medical device manufacturers currently navigating the regulatory pipeline. It is not yet clear how Medicare administrators will evaluate pending applications from developers whose products received FDA breakthrough status shortly before the automatic mechanism was discontinued.

Additionally, the precise operational capacity of alternative reimbursement channels—such as the Transformed Coverage for Efficient Technologies (TCET) pathway or local coverage determinations (LCDs) issued by regional Medicare Administrative Contractors (MACs)—remains untested at scale. Industry observers have raised doubts about whether CMS possesses adequate administrative resources to process individual evidence submissions in a timely manner without creating severe backlogs. Furthermore, it remains unknown whether Congress will intervene legislatively to modify Medicare reimbursement mandates or if device makers will alter their research strategies by focusing exclusively on technologies with immediate private insurance adoption potential.

What to watch

In the coming months, health policy analysts will monitor several critical decision points to assess the policy's real-world impact. Key focus areas include the publication of CMS’s annual Physician Fee Schedule and Inpatient Prospective Payment System (IPPS) rulemaking updates, which will provide further technical clarity on add-on payment calculations and evidence criteria.

Observers will also track the number of breakthrough device manufacturers that successfully gain entry into the TCET framework or secure localized coverage through Medicare Administrative Contractors. Furthermore, performance metrics from upcoming venture capital investment rounds in the medtech sector will offer early empirical data on whether private capital is retreating from breakthrough device development. Finally, congressional committees overseeing federal healthcare, including the House Energy and Commerce Committee and the Senate Finance Committee, may schedule oversight hearings to examine how the reimbursement changes affect patient access to novel medical technologies.

This report is based on original reporting published by Katie Palmer on Sept. 29, 2026.